Drug intelligence / Profile preview

ALC-919

Development stage: Phase 2
Lead developer: Veloce BioPharma
Modality: Small Molecules
Administration: Topical

Overview

ALC-919 is a small molecule antiviral drug developed by Alc Therapeutics for the treatment of common warts (verruca vulgaris) caused by human papillomavirus (HPV) infection. The drug reached phase 2 clinical trials, but its development has since been discontinued. Its primary therapeutic areas included infectious diseases and skin and musculoskeletal diseases. The specific mechanism of action and molecular target have not been publicly disclosed.

Beyond the preview

Go deeper on ALC-919.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ALC-919.

Explore the full profile